Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: appropriateness (49), fitness (55)

Ferinject (gynaecology) - patient information

Description: This factsheet explains what Ferinject is, what the treatment involves and what the possible side effects are.
Url: /Media/UHS-website-2019/Patientinformation/Womenshealth/Ferinject-gynaecology-patient-information.pdf

HEE Wessex ICA Internship - Information 2019-20

Description: Wessex Clinical Academic Career Programme: HEE/NIHR ICA Internships 2019/20 Information and application process For further information, con
Url: /Media/Southampton-Clinical-Research/SoAR/HEE-Wessex-ICA-Internship-Information-2019-20.pdf

Standing Financial Instructions

Description: These Standing Financial Instructions (SFIs) are issued for the regulation of the conduct of Trust members and officers in relation to
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Finance/StandingFinancialInstructions.pdf

The surgical high dependency unit - patient information

Description: This factsheet contains information about the surgical high dependency unit.
Url: /Media/UHS-website-2019/Patientinformation/Surgery/The-surgical-high-dependency-unit-1635-PIL.pdf

Neoadjuvant treatment for non-small cell lung cancer - patient information

Description: This factsheet explains what neoadjuvant treatment is and what it involves for non-small cell lung cancer.
Url: /Media/UHS-website-2019/Patientinformation/Cancercare/Neoadjuvant-treatment-for-non-small-cell-lung-cancer-3641-PIL.pdf

Cisplatin-Etoposide (intravenous and oral)

Description: Chemotherapy Protocol LUNG CANCER – SMALL CELL (SCLC) CISPLATIN-ETOPOSIDE (Intravenous / Oral) Regimen SCLC – Cisplatin-Etop
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-small-cellSCLC/Cisplatin-Etoposideintravenousandoral.pdf

Lenalidomide Ver 1.1

Description: Chemotherapy Protocol LYMPHOMA LENALIDOMIDE There are multiple versions of this protocol in use. Please ensure you have the
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Lenalidomide-Ver-1.1.pdf

FC PO (5 day)-Cyclophosphamide-Fludarabine PO 5 day Ver 1.1

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-FLUDARABINE ORAL 5 DAY (FC PO 5 day) Regimen Lymphoma – FC PO (5 day)-Cyclop
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/FC-PO-5-day-Cyclophosphamide-Fludarabine-PO-5-day-Ver-1.1.pdf

Cyclophosphamide-Etoposide PO Ver 1.1

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-ETOPOSIDE ORAL Regimen Lymphoma – Cyclophosphamide-Etoposide PO Indication P
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Cyclophosphamide-Etoposide-PO-Ver-1.1.pdf

Capecitabine 1250 (14)

Description: Chemotherapy Protocol BREAST CANCER CAPECITABINE 1250 (14 day) Regimen • Breast Cancer – Capecitabine 1250 (14 day) Indication
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Capecitabine1250-14.pdf

11 to 20 of 80

Previous 1 2 3 4 5 … Next